MiMedx Group Inc
NASDAQ:MDXG
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.51
9.14
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MDXG stock under the Base Case scenario is 6.57 USD. Compared to the current market price of 8.84 USD, MiMedx Group Inc is Overvalued by 26%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
MiMedx Group Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MDXG cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
MiMedx Group Inc
Balance Sheet Decomposition
MiMedx Group Inc
Current Assets | 172.1m |
Cash & Short-Term Investments | 88.8m |
Receivables | 54m |
Other Current Assets | 29.3m |
Non-Current Assets | 71.8m |
PP&E | 9.3m |
Intangibles | 30.6m |
Other Non-Current Assets | 31.8m |
Current Liabilities | 41.9m |
Accounts Payable | 6.9m |
Accrued Liabilities | 28.6m |
Other Current Liabilities | 6.5m |
Non-Current Liabilities | 20.9m |
Long-Term Debt | 18m |
Other Non-Current Liabilities | 2.9m |
Earnings Waterfall
MiMedx Group Inc
Revenue
|
342.8m
USD
|
Cost of Revenue
|
-57m
USD
|
Gross Profit
|
285.8m
USD
|
Operating Expenses
|
-222.4m
USD
|
Operating Income
|
63.4m
USD
|
Other Expenses
|
18.6m
USD
|
Net Income
|
82m
USD
|
Free Cash Flow Analysis
MiMedx Group Inc
USD | |
Free Cash Flow | USD |
MDXG Profitability Score
Profitability Due Diligence
MiMedx Group Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
MiMedx Group Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
MDXG Solvency Score
Solvency Due Diligence
MiMedx Group Inc's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
MiMedx Group Inc's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDXG Price Targets Summary
MiMedx Group Inc
According to Wall Street analysts, the average 1-year price target for MDXG is 12.44 USD with a low forecast of 11.11 USD and a high forecast of 14.7 USD.
Dividends
Current shareholder yield for MDXG is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 811 full-time employees. The company went IPO on 2007-08-20. The firm is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD. The AMNIOFIX and EPIFIX are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. Its EPICORD and AMNIOCORD are tissue allografts derived from umbilical cord tissue. EPIFIX is a semi-permeable, protective barrier allograft comprised of dehydrated human amnion/chorion membrane that may be used in the treatment of chronic wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. AMNIOFIX is used in surgical recovery applications including in the areas of spine, orthopedic, sports medicine and urologic.
Contact
IPO
Employees
Officers
The intrinsic value of one MDXG stock under the Base Case scenario is 6.57 USD.
Compared to the current market price of 8.84 USD, MiMedx Group Inc is Overvalued by 26%.